Development of a novel adenovirus purification process utilizing selective precipitation of cellular DNA.
The use of recombinant adenoviral vectors for vaccination and gene therapy requires the development of purification processes that are cost-effective, scalable, and capable of robust host cell DNA clearance. An adenovirus purification process was developed which incorporates selective precipitation of host cell DNA, enabling a reduction in the use of costly nucleases and chromatographic resins while substantially improving DNA and protein clearance capabilities. In this work, three cationic detergents were evaluated for their capacity to selectively precipitate DNA from adenovirus-containing cell lysate. Parameters including pH, sodium chloride concentration, nonionic surfactant concentration, and cell density were investigated during development of the precipitation step. In a novel application, the cationic detergent domiphen bromide was found to have superior selectivity for host cell DNA. In addition, domiphen bromide-induced precipitation of adenovirus was shown to be reversible, which reduces the importance of mixing. Precipitation of DNA in the cell lysate coupled with primary clarification resulted in 3 logs of DNA clearance and improved impurity clearance in the subsequent ultrafiltration step. As a result, nuclease treatment and/or anion exchange chromatography can be eliminated, or included exclusively to improve process robustness.
Goerke
Aaron R
AR
Biologics Development & Engineering, BioProcess R&D, Merck Research Laboratories, West Point, Pennsylvania 19486, USA.
To
Brian C S
BC
Lee
Ann L
AL
Sagar
Sangeetha L
SL
Konz
John O
JO
D000256:Adenoviridae / Q000254:growth & development / Q000302:isolation & purification* / Q000472:pathogenicity*; D005591:Chemical Fractionation / Q000379:methods*; D004247:DNA / Q000302:isolation & purification*; D005590:Fractional Precipitation; D014462:Ultrafiltration / Q000379:methods*; D014776:Virus Cultivation / Q000379:methods*
D004247:DNA